Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cloretazine in Relapsed or Refractory Small Cell Lung Cancer
NCT00282022Phase 2Completed
- Sponsor
- Vion Pharmaceuticals
- Start
- Sep 2005
- Primary completion
- May 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of laromustine in small cell lung cancer (SCLC), sponsored by Vion Pharmaceuticals. Started Sep 2005; status: completed.
02
Drugs
laromustine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00282022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282022.